MYLIP | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
natural killer cell	20 studies	25% ± 8%	Explore
endothelial cell	18 studies	27% ± 9%	Explore
pericyte	17 studies	28% ± 11%	Explore
B cell	15 studies	20% ± 4%	Explore
fibroblast	14 studies	28% ± 10%	Explore
T cell	13 studies	25% ± 12%	Explore
CD8-positive, alpha-beta T cell	13 studies	21% ± 6%	Explore
smooth muscle cell	10 studies	26% ± 11%	Explore
CD16-positive, CD56-dim natural killer cell, human	10 studies	23% ± 6%	Explore
CD4-positive, alpha-beta T cell	10 studies	24% ± 9%	Explore
CD16-negative, CD56-bright natural killer cell, human	9 studies	23% ± 6%	Explore
macrophage	8 studies	21% ± 5%	Explore
mature NK T cell	7 studies	23% ± 4%	Explore
mucosal invariant T cell	7 studies	23% ± 5%	Explore
naive B cell	7 studies	22% ± 5%	Explore
endothelial cell of vascular tree	7 studies	22% ± 7%	Explore
gamma-delta T cell	7 studies	24% ± 6%	Explore
regulatory T cell	7 studies	25% ± 7%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	6 studies	21% ± 3%	Explore
epithelial cell	6 studies	33% ± 21%	Explore
type II pneumocyte	5 studies	19% ± 2%	Explore
effector memory CD8-positive, alpha-beta T cell	5 studies	22% ± 4%	Explore
precursor B cell	5 studies	30% ± 5%	Explore
immature B cell	5 studies	32% ± 15%	Explore
type I pneumocyte	5 studies	20% ± 3%	Explore
basal cell	5 studies	28% ± 7%	Explore
CD8-positive, alpha-beta memory T cell	5 studies	28% ± 5%	Explore
memory B cell	5 studies	22% ± 4%	Explore
conventional dendritic cell	4 studies	28% ± 14%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	4 studies	23% ± 3%	Explore
capillary endothelial cell	4 studies	21% ± 1%	Explore
connective tissue cell	4 studies	24% ± 4%	Explore
abnormal cell	4 studies	18% ± 2%	Explore
endothelial cell of artery	4 studies	22% ± 8%	Explore
myeloid cell	4 studies	24% ± 7%	Explore
ciliated cell	4 studies	32% ± 18%	Explore
oligodendrocyte	4 studies	27% ± 10%	Explore
CD4-positive, alpha-beta memory T cell	4 studies	24% ± 5%	Explore
ionocyte	3 studies	21% ± 5%	Explore
classical monocyte	3 studies	26% ± 11%	Explore
glomerular endothelial cell	3 studies	41% ± 5%	Explore
monocyte	3 studies	16% ± 0%	Explore
myofibroblast cell	3 studies	21% ± 3%	Explore
pro-B cell	3 studies	24% ± 1%	Explore
effector memory CD4-positive, alpha-beta T cell	3 studies	25% ± 3%	Explore
glutamatergic neuron	3 studies	24% ± 8%	Explore
mast cell	3 studies	21% ± 5%	Explore
T follicular helper cell	3 studies	36% ± 7%	Explore
group 3 innate lymphoid cell	3 studies	26% ± 7%	Explore
innate lymphoid cell	3 studies	30% ± 14%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
peripheral blood	7 studies	23% ± 8%	Explore
lung	6 studies	22% ± 4%	Explore
brain	4 studies	25% ± 6%	Explore
kidney	3 studies	18% ± 2%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
ovary	99%	2626.95	179 / 180	100%	48.70	430 / 430
intestine	100%	2915.51	966 / 966	99%	33.37	522 / 527
breast	100%	3745.32	459 / 459	99%	59.83	1104 / 1118
prostate	100%	2139.98	245 / 245	99%	42.95	495 / 502
stomach	100%	2191.72	359 / 359	99%	35.10	282 / 286
thymus	100%	4865.88	653 / 653	99%	96.94	596 / 605
lung	100%	3666.19	576 / 578	98%	42.24	1132 / 1155
kidney	100%	2112.38	89 / 89	95%	46.91	860 / 901
bladder	100%	2925.67	21 / 21	95%	43.89	481 / 504
uterus	100%	4426.68	170 / 170	95%	41.29	436 / 459
skin	94%	2359.58	1703 / 1809	97%	57.44	458 / 472
esophagus	100%	2150.90	1439 / 1445	90%	27.55	165 / 183
pancreas	94%	997.26	309 / 328	95%	25.24	169 / 178
brain	84%	847.90	2226 / 2642	92%	19.79	649 / 705
adrenal gland	98%	2124.89	253 / 258	73%	21.93	168 / 230
adipose	100%	3935.89	1204 / 1204	0%	0	0 / 0
blood vessel	100%	5454.43	1335 / 1335	0%	0	0 / 0
spleen	100%	3861.96	241 / 241	0%	0	0 / 0
ureter	0%	0	0 / 0	100%	33.76	1 / 1
eye	0%	0	0 / 0	98%	52.10	78 / 80
muscle	97%	1486.49	781 / 803	0%	0	0 / 0
peripheral blood	97%	2759.75	902 / 929	0%	0	0 / 0
tonsil	0%	0	0 / 0	93%	45.14	42 / 45
lymph node	0%	0	0 / 0	90%	23.25	26 / 29
heart	89%	956.35	769 / 861	0%	0	0 / 0
liver	10%	64.97	22 / 226	28%	5.81	115 / 406
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0

III. Associated gene sets

GO_0010989	Biological process	negative regulation of low-density lipoprotein particle clearance
GO_0045732	Biological process	positive regulation of protein catabolic process
GO_0016567	Biological process	protein ubiquitination
GO_0006511	Biological process	ubiquitin-dependent protein catabolic process
GO_0007399	Biological process	nervous system development
GO_0010977	Biological process	negative regulation of neuron projection development
GO_0032803	Biological process	regulation of low-density lipoprotein particle receptor catabolic process
GO_0031648	Biological process	protein destabilization
GO_0042632	Biological process	cholesterol homeostasis
GO_0005856	Cellular component	cytoskeleton
GO_0005829	Cellular component	cytosol
GO_0005886	Cellular component	plasma membrane
GO_0061630	Molecular function	ubiquitin protein ligase activity
GO_0004842	Molecular function	ubiquitin-protein transferase activity
GO_0008092	Molecular function	cytoskeletal protein binding
GO_0005515	Molecular function	protein binding
GO_0046872	Molecular function	metal ion binding

IV. Literature review

[source]

Gene name	MYLIP
Protein name	RING-type E3 ubiquitin transferase (EC 2.3.2.27) E3 ubiquitin-protein ligase MYLIP (EC 2.3.2.27) (Inducible degrader of the LDL-receptor) (Idol) (Myosin regulatory light chain interacting protein) (MIR) (RING-type E3 ubiquitin transferase MYLIP)
Synonyms	PP5242 hCG_37431 BZF1 BM-023 IDOL
Description	FUNCTION: E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Activity depends on E2 enzymes of the UBE2D family. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR. .
Accessions	ENST00000356840.8 [Q8WY64-1] Q8WY64 Q5TIA5 ENST00000349606.4

MYLIP report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review